Quick Answer
Vanda Pharmaceuticals Inc. reported Revenue (ASC 606) of $216.10 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $216.10M | +8.7% |
| 2024 | $198.77M | +3.2% |
| 2023 | $192.64M | -24.3% |
| 2022 | $254.38M | -5.3% |
| 2021 | $268.68M | +8.3% |
| 2020 | $248.17M | +9.2% |
| 2019 | $227.19M | +17.6% |
| 2018 | $193.12M | +17.0% |
| 2017 | $165.08M | +13.1% |
| 2016 | $146.02M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.26M | +18.1% | +7.0% |
| June 30, 2025 | $52.59M | +4.2% | +5.1% |
| March 31, 2025 | $50.04M | +5.4% | +5.0% |
| September 30, 2024 | $47.65M | +22.8% | -5.6% |
| June 30, 2024 | $50.47M | +9.6% | +6.3% |
| March 31, 2024 | $47.46M | -24.1% | +22.3% |
| September 30, 2023 | $38.81M | -40.6% | -15.7% |
| June 30, 2023 | $46.06M | -28.5% | -26.3% |
- Vanda Pharmaceuticals Inc. showed an increase of +8.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Vanda Pharmaceuticals Inc.’s revenue (asc 606) has grown by 48.0% (from $146.02 million to $216.10 million).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: